97 related articles for article (PubMed ID: 9723101)
1. [Pharmacologic treatment of dyslipidemias: Analysis of initiation recommendations and drug selection].
Davidoff P
Rev Med Chil; 1991 Dec; 119(12):1423-32. PubMed ID: 9723101
[TBL] [Abstract][Full Text] [Related]
2. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
Yeshurun D; Hamood H; Morad N; Naschitz J
Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
[TBL] [Abstract][Full Text] [Related]
4. [Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months].
Davidoff P; Ruiz F; Varas MA; García de los Ríos M; Silva MA; González G; Tapia JC
Rev Med Chil; 1991 Oct; 119(10):1140-6. PubMed ID: 1845208
[TBL] [Abstract][Full Text] [Related]
5. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
7. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
[TBL] [Abstract][Full Text] [Related]
8. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
[TBL] [Abstract][Full Text] [Related]
9. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
Tonutti L; Taboga C; Noacco C
Minerva Med; 1991 Oct; 82(10):657-63. PubMed ID: 1745376
[TBL] [Abstract][Full Text] [Related]
11. Management of hyperlipidemia: goals for the prevention of atherosclerosis.
Illingworth DR
Clin Invest Med; 1990 Aug; 13(4):211-8. PubMed ID: 2208837
[TBL] [Abstract][Full Text] [Related]
12. Treating hyperlipidemia, Part III: Drug therapy.
Smith DA; Karmally W; Brown WV
Geriatrics; 1987 Aug; 42(8):55-9, 62. PubMed ID: 3110017
[TBL] [Abstract][Full Text] [Related]
13. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacologic treatment of lipid metabolism disorders].
Gmiński J
Wiad Lek; 1996; 49(7-12):173-81. PubMed ID: 9214849
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
16. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
17. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
18. Management of dyslipidemia in the high-risk patient.
Stein EA
Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
[TBL] [Abstract][Full Text] [Related]
19. [Drug treatment of hyperlipidemia].
Zazgornik J; Koch S
Wien Med Wochenschr Suppl; 1989; 105():20-3. PubMed ID: 2694628
[TBL] [Abstract][Full Text] [Related]
20. [Hyperlipidemia: therapeutic principles in clinical practice].
Müller-Wieland D; Krone W
Med Klin (Munich); 2003 Dec; 98(12):739-43. PubMed ID: 14685674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
